Authors
Steven I Sherman, Lori J Wirth, Jean-Pierre Droz, Michael Hofmann, Lars Bastholt, Renato G Martins, Lisa Licitra, Michael J Eschenberg, Yu-Nien Sun, Todd Juan, Daniel E Stepan, Martin J Schlumberger
Publication date
2008/7/3
Journal
New England Journal of Medicine
Volume
359
Issue
1
Pages
31-42
Publisher
Massachusetts Medical Society
Description
Background The expression of vascular endothelial growth factor (VEGF) is characteristic of
differentiated thyroid cancer and is associated with aggressive tumor behavior and a poor
clinical outcome. Motesanib diphosphate (AMG 706) is a novel oral inhibitor of VEGF
receptors, platelet-derived growth-factor receptor, and KIT.
Total citations
20082009201020112012201320146506163583439
Scholar articles
SI Sherman, LJ Wirth, JP Droz, M Hofmann, L Bastholt… - New England Journal of Medicine, 2008